UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction of incorporation or organization) |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip code)
(
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading | | Name of each exchange |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On September 22, 2026, the Board of Directors (the “Board”) of MeiraGTx Holdings plc (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Alan M. Sebulsky to the Board as a Class I director, effective September 23, 2026, with a term that expires at the Company’s 2028 annual meeting of shareholders when Class I directors are up for re-election and until his successor is duly elected and qualified. Mr. Sebulsky has been appointed to serve as a member of the Science and Technology Committee. Mr. Sebulsky was recommended as a potential candidate for election to our Board by the Company’s senior management.
Mr. Sebulsky has served as the Managing Member of Apothecary Capital LLC since its reestablishment in April 2026. Mr. Sebulsky previously served as a Partner and Portfolio Manager at Adage Capital Management, LP. from July 2012 to April 2026, where he was responsible for managing a biopharmaceutical portfolio. Prior to that Mr. Sebulsky served as a Portfolio Manager at BBT Capital Management Advisory LLC from April 2003 to March 2012, through his role as the Managing Partner of Apothecary Capital LLC over the same period. From 1994 to 2002, Mr. Sebulsky held various positions, including as a Managing Director at Lincoln Capital Management, a private investment management firm, where he was responsible for investments in the healthcare industry. Mr. Sebulsky currently serves as a member of the board of directors of Parabilis Medicines, Inc and previously served on the boards of directors of Jazz Pharmaceuticals PLC and Arrow International, Inc. Mr. Sebulsky received a B.B.A. in finance and economics and an M.S. in finance from the University of Wisconsin, Madison.
Mr. Sebulsky will be eligible to receive compensation for his service as a member of the Board pursuant to the terms of the Company’s Non-Employee Director Compensation Program, as amended from time to time.
We expect that Mr. Sebulsky will enter into the Company’s standard form of indemnification agreement for its directors and officers. Mr. Sebulsky was not selected as a director pursuant to any arrangement or understanding between him and any other person. There are no related party transactions between the Company and Mr. Sebulsky.
Item 7.01.Regulation FD Disclosure.
On September 23, 2026, the Company issued a press release announcing the appointment of Alan M. Sebulsky to the Board, a copy of which is filed as Exhibit 99.1 hereto and incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01.Financial Statements and Exhibits.
(d) | Exhibits. |
Exhibit No. | | Description |
99.1 | Press release of MeiraGTx Holdings plc, dated September 23, 2026. | |
104 |
| Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 23, 2026 | ||
MEIRAGTX HOLDINGS PLC | ||
By: | /s/ Richard Giroux | |
Name: | Richard Giroux | |
Title: | Chief Financial Officer and Chief Operating Officers | |
Exhibit 99.1
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.
Mr. Sebulsky is a veteran healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in public company investment, financial strategy, portfolio evaluation and growth, and board leadership. Mr. Sebulsky most recently served as Partner and Portfolio Manager at Adage Capital Management for the past 14 years, where he led a team overseeing a diversified biopharmaceutical portfolio with over $2 billion in assets. Prior to this, he founded Apothecary Capital, an asset management firm focused on investments across the healthcare and biopharmaceutical sectors. He reestablished Apothecary in April 2026 and currently serves as the Managing Member.
Mr. Sebulsky currently serves on the Board of Directors of Parabilis Medicines, Inc. and previously served on the Boards of Directors and Audit Committees for both Jazz Pharmaceuticals and Arrow International, two publicly traded healthcare companies, and on the boards of three private healthcare companies in which Apothecary Capital invested. In these roles, he worked closely with company leadership to advance portfolio, commercial and business strategy.
Mr. Sebulsky holds an M.S. in finance and a B.B.A. in finance and economics from the University of Wisconsin–Madison.
“We are delighted to welcome Alan to our Board of Directors,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “I have known Alan for 25 years and I have always had the highest respect for him both professionally and personally. His decades of investing in and working with biopharmaceutical companies brings a valuable perspective to the board which is particularly important as we continue to transform MeiraGTx into a commercial company.”
Keith Harris, Chairman of the Board of Directors of MeiraGTx, added, “I am pleased that Alan is joining our board. He brings an extensive wealth of knowledge of our sector and public company experience. We look forward to his invaluable assistance in helping the further growth of our Company.”
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs use local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases, in the eye, radiation-induced xerostomia, and Parkinson’s disease. MeiraGTx uses its innovative technology in optimization of capsids, promoters and novel translational control elements to develop best in class, potent, safe viral vectors. MeiraGTx’s broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, including two that are licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure. In addition, MeiraGTx has developed a proprietary manufacturing platform process over 10 years based on more than 20 different viral vectors with leading yield and quality aspects and commercial readiness. Uniquely, MeiraGTx has developed a novel technology for in vivo delivery of any biologic therapeutic using oral small molecules. This transformative riboswitch gene regulation technology allows
precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo delivery of metabolic peptides, including GLP-1, GIP, Glucagon, Amylin, PYY and Leptin, as well as cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally PNS targets addressing long term intractable pain. MeiraGTx has developed the technology to apply genetic medicine to common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.
For more information, please visit www.meiragtx.com.
Contacts
Investors:
MeiraGTx
Investors@meiragtx.com
or
Media:
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com